Campbell & CO Investment Adviser LLC Invests $416,000 in Tarsus Pharmaceuticals, Inc. $TARS

Campbell & CO Investment Adviser LLC acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,273 shares of the company’s stock, valued at approximately $416,000.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock worth $66,000 after purchasing an additional 339 shares during the last quarter. Quarry LP lifted its stake in shares of Tarsus Pharmaceuticals by 20.0% in the 1st quarter. Quarry LP now owns 3,599 shares of the company’s stock worth $185,000 after purchasing an additional 599 shares during the period. AlphaQuest LLC purchased a new position in shares of Tarsus Pharmaceuticals in the first quarter worth approximately $189,000. Allianz Asset Management GmbH bought a new stake in Tarsus Pharmaceuticals during the second quarter valued at approximately $227,000. Finally, FORA Capital LLC bought a new stake in Tarsus Pharmaceuticals during the first quarter valued at approximately $271,000. Institutional investors own 90.01% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total transaction of $332,220.00. Following the completion of the transaction, the chief executive officer directly owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William J. Phd Link sold 27,116 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares in the company, valued at approximately $8,169,924. The trade was a 15.91% decrease in their position. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TARS has been the topic of several recent research reports. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. HC Wainwright raised their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a report on Monday, October 20th. The Goldman Sachs Group reissued a “neutral” rating and set a $51.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, November 6th. Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $69.83.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $72.92 on Monday. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $76.81. The business has a 50-day moving average price of $64.34 and a 200-day moving average price of $52.07. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -36.10 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The business had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.